BioKangtai: Trivalent influenza virus split vaccine approved for clinical trials

BioKangtai announced that recently, the trivalent influenza virus split vaccine developed by the company and Lanzhou Bailing Biotechnology Co., Ltd. has received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration. This vaccine is suitable for individuals aged 3 years and older and can stimulate the body to produce immunity against the influenza virus, used for the prevention of influenza caused by vaccine-related strains. The company will promptly carry out relevant clinical trial work. If the vaccine development is successful, it will help further enrich the company's product layout and enhance its core competitiveness and market position